Table 2 Associations between MTC02 expression results and ERG negative prostate cancer phenotype

All cancers

4.15

4.2

17.1

34.2

44.5

PSA preoperative

<4

423

4.02

18.2

33.57

44.21

0.0372

4-10

2.43

3.88

17.94

35.42

42.76

10-20

925

5.08

16.11

32.76

46.05

>20

337

3.56

12.76

31.16

52.52

Tumor stage

pT2

2.74

4.42

20.02

36.24

39.31

< 0.0001

pT3a

859

4.07

13.62

32.83

49.48

pT3b

515

3.3

8.16

25.83

62.72

pT4

26

0

7.69

30.77

61.54

Gleason grade

≤3 + 3

906

6.62

25.17

38.19

30.0

< 0.0001

3 + 4

2.32

3.67

17.02

36.29

43.02

4 + 3

685

3.5

11.09

26.86

58.54

≥4 + 4

226

1.77

3.98

19.91

74.34

Lymph node metastasis

N0

2.41

4.28

16.09

33.85

45.78

< 0.0001

N+

230

3.04

6.52

23.04

67.39

Surgical margin

Negative

3.29

4.01

18.09

35.2

42.71

< 0.0001

Positive

783

4.34

13.28

29.89

52.49